Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.65 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.65 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | GCKR | Q14397 | 3/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12089894 | 0.89 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL2951055 | 0.80 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL6658178 | 0.80 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF | |
| SCHEMBL16824 | 0.79 | GCKR (0.51) | GCKR | |
| SCHEMBL17181 | 0.78 | HSD11B1 (0.43) | GCKR | |
| SCHEMBL12078657 | 0.78 | HSD11B1 (0.43) | GCKR | |
| SCHEMBL18318 | 0.78 | HSD11B1 (0.43) | GCKR | |
| Hydrochloric Acid SCHEMBL16799 | 0.77 | RAD52 (0.44) | GCKR | |
| Hydrochloric Acid SCHEMBL29627 | 0.77 | RAD52 (0.44) | GCKR | |
| SCHEMBL588544 | 0.77 | SLC6A4 (0.81) | SLC6A4SLC6A3SLC6A2CYP2D6MITF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-8431563-B2 | Compounds that interact with glucokinase regulatory protein for the treatment of diabetes | AMGEN INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-09-06 | — | — | US | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225854-A1 | COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | GCKR, GCK, SLC5A2 | SLC6A4 3143/4885SLC6A3 3199/4885SLC6A2 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.